Three new products will be launched globally.
Allenex (through the subsidiary Olerup SSP AB) has entered into an agreement with the Australian company Conexio Genomics Pty Ltd (”Conexio”) to the effect that the parties’ co-operation is deepened and extended in time. In May 2011 Allenex announced a five year exclusive and global marketing and sales agreement with Conexio for SBT Resolver™ for HLA typing using the SBT technology. Software for sequence analysis was also included in the agreement. Allenex and Conexio have now decided to prolong the agreement for an additional period of two years, which means that the co-operation is extended until at least April 2018. Further, Allenex has been granted the right to market and sell three new products from Conexio: GammaType™, MPS Resolver™, Next Generation Sequencing (NGS) HLA products and another new NGS product with proprietary rights. Software for sequence analysis is also included. Two of these products, GammaType™ and the new NGS product, are unique and do not have any equivalent competitors. All products will be added to Allenex product portfolio from 2014 and in the years to come.
With these additions, the Allenex offering to customers within transplantation diagnostics will be extended. Allenex retains its exclusive distribution rights in Europe, North and South America, the Middle East, Africa and parts of Asia under the Agreement. Australia, New Zealand and Taiwan have previously been excluded from the co-operation and Allenex will not have distribution rights in these markets according to the new agreement either. Allenex will, however, waive its exclusive rights under the agreement for certain selected Asian market such as Singapore, Malaysia, Indonesia, Thailand, Vietnam, Cambodia, Hong Kong and Japan, in order to focus on those other markets where the parties see the greatest potential. Allenex will, however, retain non-exclusive rights to distribute in these countries.
Allenex’ CEO Anders Karlsson comments:
”I am very happy that we can agree on this new, large and important step in our co-operation with Conexio. Sales of SBT Resolver™ are developing well and now, we ensure access to Conexio’s world leading products until at least April 2018. With this addition of new products, our strong offering within transplantation diagnostics becomes even more complete.”
For more information please contact:
Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail: anders.karlsson@allenex.se
Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on June 13, 2014, at 10.30 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the Allenex group.
Tags: